Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8175192 | 0.89 | FKBP1A (0.47) | SMN1; SMN2NPC1RAB9ANPSR1PREP | |
| SCHEMBL10174845 | 0.85 | TMEM97 (0.48) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11390766 | 0.85 | ALDH1A1 (0.48) | SMN1; SMN2NPC1RAB9APREPAGTR2 | |
| SCHEMBL11390768 | 0.85 | ALDH1A1 (0.48) | SMN1; SMN2NPC1RAB9APREPAGTR2 | |
| SCHEMBL8481532 | 0.84 | POLB (0.47) | SMN1; SMN2NPC1RAB9APREPAGTR2 | |
| SCHEMBL11387330 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL11387333 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL19221747 | 0.83 | SLC6A2 (0.48) | SMN1; SMN2NPC1RAB9AKMT2AAGTR2 | |
| SCHEMBL29921 | 0.82 | AGTR2 (0.56) | SMN1; SMN2NPC1RAB9AAGTR2 | |
| SCHEMBL6515997 | 0.82 | AGTR2 (0.56) | SMN1; SMN2NPC1RAB9AAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| EP-2027143-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | SMN1; SMN2 1942/4885NPC1 726/4885RAB9A 3044/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | SMN1; SMN2 1942/4885NPC1 726/4885RAB9A 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.